KDM3B inhibitors disrupt the oncogenic activity of PAX3-FOXO1 in fusion-positive rhabdomyosarcoma

Abstract Fusion-positive rhabdomyosarcoma (FP-RMS) is an aggressive pediatric sarcoma driven primarily by the PAX3-FOXO1 fusion oncogene, for which therapies targeting PAX3-FOXO1 are lacking. Here, we screen 62,643 compounds using an engineered cell line that monitors PAX3-FOXO1 transcriptional acti...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yong Yean Kim, Berkley E. Gryder, Ranuka Sinniah, Megan L. Peach, Jack F. Shern, Abdalla Abdelmaksoud, Silvia Pomella, Girma M. Woldemichael, Benjamin Z. Stanton, David Milewski, Joseph J. Barchi, John S. Schneekloth, Raj Chari, Joshua T. Kowalczyk, Shilpa R. Shenoy, Jason R. Evans, Young K. Song, Chaoyu Wang, Xinyu Wen, Hsien-Chao Chou, Vineela Gangalapudi, Dominic Esposito, Jane Jones, Lauren Procter, Maura O’Neill, Lisa M. Jenkins, Nadya I. Tarasova, Jun S. Wei, James B. McMahon, Barry R. O’Keefe, Robert G. Hawley, Javed Khan
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Nature Portfolio 2024-02-01
coleção:	Nature Communications
Acesso em linha:	https://doi.org/10.1038/s41467-024-45902-y
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!